Publications by authors named "D H Rubin"
Objective: Etrasimod is an oral, once-daily, selective sphingosine 1-phosphate (S1P) receptor modulator for the treatment of moderately to severely active ulcerative colitis (UC). S1P receptor expression on cardiac cells is involved in cardiac conduction. We report cardiovascular treatment-emergent adverse events (TEAEs) associated with S1P receptor modulators and other cardiovascular events in the etrasimod UC clinical programme.
View Article and Find Full Text PDFIntroduction: Patients with ulcerative colitis (UC) and prior biologic failure may have reduced or delayed efficacy with subsequent advanced therapies. This analysis evaluated the efficacy and safety of ozanimod during the True North (TN) study and its open-label extension (OLE) in biologic-exposed patients with UC.
Methods: TN was a randomized, placebo-controlled 52-week trial (10-week induction, 42-week maintenance period).
Article Synopsis
- Spondyloarthritis (SpA) is a common condition among patients with inflammatory bowel disease (IBD), affecting up to 39% of individuals but lacks well-defined risk factors.
- The study involved assessing 588 IBD patients using two validated questionnaires to identify SpA symptoms, revealing significant positive screenings for SpA among these patients.
- Key risk factors for positive SpA screens included being female, older age, a history of smoking, bowel surgery, and exposure to biologic treatments, with a concerning number of undiagnosed cases identified.
Article Synopsis
- Spondyloarthritis (SpA) is a common issue for patients with inflammatory bowel disease (IBD), and using specific screening tools could help identify it earlier and improve treatment.
- A study analyzed 669 IBD patients using two questionnaires (DETAIL and IBIS-Q) to check for SpA symptoms; many patients screened positive, with more showing axial symptoms rather than peripheral issues.
- The results highlighted that a significant number of patients with IBD might have undiagnosed SpA, particularly with the IBIS-Q being more effective in identifying potential cases, indicating a need for better rheumatology referrals for these patients.
Vasculitic neuropathy is caused by inflammatory destruction of nerve blood vessels resulting in nerve ischemia. Nerve vasculitis can be divided into two categories based on vessel size - large arteriole vasculitis (≥75 µm) and microvasculitis (<75 µm). Herein, we characterize the clinical features of nerve large-arteriole vasculitis compared to nerve microvasculitis.
View Article and Find Full Text PDF